Find a Clinical Trial
Is a clinical trial right for you? Search our database to find studies for which you may be eligible.
Enasidenib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With an IDH2 Mutation
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT04203316
Principal Investigator:
Kevin Ginn
A phase 1/2 study of CPX-351 (NSC#775341) Alone followed by Fludarabine, Cytarabine and G-CSF (FLAG) for Children with Relapsed Acute Myeloid Leukemia (AML)
Study Type: Treatment
Phase: I/II
NCTID: NCT02642965
Principal Investigator:
Keith August
A Phase IB/II Study Evaluating the Safety and Efficacy of Idasanutlin in Combination with Cytarabine and Daunorubicin in Patients Newly Diagnosed with Acute Myeloid Leukemia (AML) and the Safety and Efficacy of Idasanutlin in the Maintenance of First AML Complete Remission
Phase III Randomized Study of Crenolanib versus Midostaurin Administered Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed Subjects with FLT3 Mutated Acute Myeloid Leukemia
A first in human, open-label, multicenter Study of VOR33 in patients with Acute Myeloid Leukemia who are at High-Risk for Leukemia Relapse Following Hematopoietic Transplant.
Study Type:
Phase:
NCTID:
Principal Investigator:
An Open-Label, Phase I, Multi-Center Study to Determine in Relapsed/Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome or B-Cell Non-Hodgkin Lymphoma Patients the Recommended Dose of CYAD-02 After A Non-Myeloablative Preconditioning Chemotherapy Followed By A Potential CYAD-02 Consolidation Cycle for Non-Progressive Patients CYCLE-1 ? CYAD-02 NKG2D CAR-T Clinical dEvelopment
Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome
Study Type: Treatment
Phase: III
NCTID: NCT02521493
Principal Investigator:
Keith August
A Phase 1 Study of ASP2215 in Combination with Induction and Consolidation Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukemia
Stopping Tyrosine Kinase Inhibitors in Affecting Treatment-Free Remission in Patients With Chronic Phase Chronic Myeloid Leukemia
Study Type: Treatment
Phase: Feasibility/Pilot
NCTID: NCT03817398
Principal Investigator:
Keith August